摘要
Transcatheter edge-to-edge repair(TEER)of the mitral valve has emerged as a standard treatment for patients with severe degenerative mitral regurgitation at high or prohibitive surgical risk.The devices approved by the Food and Drug Administration including MitraClip(Abbott Vascular,California,USA)and PASCAL(Edwards Lifesciences,California,USA)cost over$33,000 in western countries.[1]This pricing presents a significant economic burden especially in developing countries,where TEER devices are typically not covered by health insurance.
基金
supported by the National Key R&D Program of China(2022YFC2503400)
Major science and technology special plan project of Yunnan Province(202302AA310045)
Yunnan Provincial Clinical Research Center for Cardiovascular Diseases(202102AA310002).
